JP Morgan Chase’s Corbus Pharmaceuticals CRBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-103
Closed -$6K 5668
2020
Q3
$6K Buy
+103
New +$18.7K ﹤0.01% 5310
2020
Q2
Sell
-447
Closed -$70K 5414
2020
Q1
$70K Hold
447
﹤0.01% 4625
2019
Q4
$73K Buy
+447
New +$66.1K ﹤0.01% 5000
2019
Q2
Sell
-130
Closed -$27K 5790
2019
Q1
$27K Hold
130
﹤0.01% 5325
2018
Q4
$23K Buy
+130
New +$25.9K ﹤0.01% 5292

Other funds holding CRBP

JP Morgan Chase's CRBP Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Corbus Pharmaceuticals (CRBP) in Q2 2026: 6,854 shares worth $61.5K. The stake represents ﹤0.01% of the portfolio and ranks #6341 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in CRBP as recently as Q2 2025.

JP Morgan Chase first reported a position in CRBP in Q2 2016 and has held it in 33 quarters since. The position peaked at $2.42M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • JP Morgan Chase held 6,854 shares of Corbus Pharmaceuticals worth $61.5K as of Q2 2026.
  • Corbus Pharmaceuticals was a new JP Morgan Chase position in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6341 holding.
  • JP Morgan Chase first reported a position in Corbus Pharmaceuticals in Q2 2016 and has held it in 33 quarters since.
  • JP Morgan Chase's Corbus Pharmaceuticals position peaked at $2.42M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.